These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 23001911)

  • 1. Follicular lymphoma: 2012 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular lymphoma: 2014 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2014 Apr; 89(4):429-36. PubMed ID: 24687887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicular lymphoma: 2011 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follicular lymphoma: 2015 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2015 Dec; 90(12):1171-8. PubMed ID: 26769125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follicular lymphoma: 2018 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2018 Feb; 93(2):296-305. PubMed ID: 29314206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follicular lymphoma: 2020 update on diagnosis and management.
    Freedman A; Jacobsen E
    Am J Hematol; 2020 Mar; 95(3):316-327. PubMed ID: 31814159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular lymphoma: 2023 update on diagnosis and management.
    Jacobsen E
    Am J Hematol; 2022 Dec; 97(12):1638-1651. PubMed ID: 36255040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
    Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
    Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma.
    Voso MT; Hohaus S; Moos M; Haas R
    Blood; 1997 May; 89(10):3763-8. PubMed ID: 9160682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
    Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current clinical aspects of follicular lymphoma].
    Dreyling M
    Ther Umsch; 2010 Oct; 67(10):511-6. PubMed ID: 20886457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
    Northup JK; Gadre SA; Ge Y; Lockhart LH; Velagaleti GV
    Eur J Haematol; 2007 Feb; 78(2):152-6. PubMed ID: 17313561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.